Drug Type Small molecule drug |
Synonyms Amlodipine besylate/olmersartan medoxomil/rosuvastatin calcium, Amlodipine/olmesartan/rosuvastatin, Olmersartan medoxomil/amlodipine besilate/rosuvastatin calcium + [5] |
Target |
Action antagonists, inhibitors, blockers |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors), VDCCs blockers(Voltage-gated calcium channel blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date South Korea (27 Feb 2019), |
Regulation- |
Molecular FormulaC22H28CaFN3O6S |
InChIKeyAVDMILNVMOXCHF-DHMAKVBVSA-N |
CAS Registry147098-20-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Essential Hypertension | South Korea | 27 Feb 2019 | |
Primary hypercholesterolemia | South Korea | 27 Feb 2019 |